Research search

Reset all

287 matching records Analyze trends Open JSON Open API Download SQLite

Keyword search Author

Substances Psilocybin 3833 Psilocin 553

Date range quick select Last month Last year Last 5 years All time Custom range

BibTeX RIS CSV JSON SQLite

Executed search Journal: ClinicalTrials.gov 287 matching records are displayed.

Clear search

Latest Publications

Most recently published records currently stored in SQLite.

1-20

Last updated: Jul 2, 2026 22:01 UTC

Checking for newly published papers…

Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study

Neuroethics · 2026-07-31

Chwyl Christina, Bazinet Alissa, Wilson-Poe Adrianne R., Hoffman Kim, Pertl Kellie, Wolf R. Cameron, Korthuis P. Todd, Luoma Jason B.

DOI 10.1007/s12152-026-09645-5

Crossref Published psilocybin General Qualitative Study

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

ClinicalTrials.gov · 2026-07-01

University of Wisconsin, Madison

ClinicalTrials.gov CLINICAL TRIAL psilocybin ConsciousnessWellbeingPsychological Flexibility Other

Meskalin / Mescaline

Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30

Schüller Thomas

DOI 10.5281/zenodo.21113821

OpenAlex Published psilocybin Receptor PharmacologyRandomized Controlled TrialToxicity Randomized Controlled Trial

DMT und Ayahuasca / DMT and Ayahuasca

Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30

Schüller Thomas

DOI 10.5281/zenodo.21113899

OpenAlex Published psilocybin Toxicity Other

DMT und Ayahuasca / DMT and Ayahuasca

Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30

Schüller Thomas

DOI 10.5281/zenodo.21113898

OpenAlex Published psilocybin Toxicity Other

Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia

Revista CienciaUANL · 2026-06-30

Armando Ordaz-Hernández, M. Corona-Ramírez, Israel Jesús Orlando Guerrero

DOI 10.29105/cienciauanl29.138-5

OpenAlex Published psilocybin DepressionAnxietyPTSDAddictionNeuroplasticityReceptor PharmacologySpirituality Other

Meskalin / Mescaline

Zenodo (CERN European Organization for Nuclear Research) · 2026-06-30

Schüller Thomas

DOI 10.5281/zenodo.21113820

OpenAlex Published psilocybin Receptor PharmacologyRandomized Controlled TrialToxicity Randomized Controlled Trial

Usos recreativos, medicinales y etnobotánicos de hongos alucinógenos: una revisión

Multidisciplinary Collaborative Journal · 2026-06-30

Érika A. Chillogallo-Torres, Marcos D. Calle-Morán, Karen P. Cando-Andrade, Álex R. Morocho-Malla, E. Noemí Luzuriaga-Rodríguez

DOI 10.70881/mcj/v4/n3/164

OpenAlex Published psilocybinpsilocin DepressionAddictionOCDReview ArticleSafetyInflammation Review Article

Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait?

Unknown journal · 2026-06-30

Mellica Askari, Varun Surapaneni

DOI 10.32942/x2fd49

OpenAlex Published psilocybin Mechanism of ActionReceptor PharmacologyGenomics Other

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms

Journal of Drug Issues · 2026-06-30

Haley M Hummel, Alexia N Obrochta, David C. R. Kerr, Anita Cservenka

DOI 10.1177/00220426261466154

OpenAlex Published psilocybin DepressionAnxietyAddictionChronic PainObservational StudyToxicity Observational Study

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Unknown journal · 2026-06-30

Smith SA, Mohammad H, Lee LHN, Dennett L, Smith S, Burback L, Winkler O, Greenshaw A, Jetly R, Kennedy SH, Bhat V, Swainson J, Vermetten E, Cao B, Li XM, Zhang Y.

DOI 10.1007/s00213-026-07110-y PubMed 42380668

Europe PMC Published psilocybin DepressionAnxietyPTSDEmotional ProcessingClinical TrialReview Article Clinical Trial

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

ClinicalTrials.gov · 2026-06-30

Centre Hospitalier Universitaire de Nīmes

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAddictionSafety Other

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

ClinicalTrials.gov · 2026-06-30

Sunstone Medical

ClinicalTrials.gov CLINICAL TRIAL psilocybin PTSDClinical TrialSafety Clinical Trial

Psilocybin shows mixed results for patients with treatment-resistant depression

The Brown University Psychopharmacology Update · 2026-06-30

Authors unavailable

DOI 10.1002/pu.31461

Crossref Published psilocybin DepressionClinical TrialTreatment-Resistant Depression Clinical Trial

Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation

The Brown University Psychopharmacology Update · 2026-06-30

Authors unavailable

DOI 10.1002/pu.31467

Crossref Published psilocybin Addiction Other

Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review

Journal of Affective Disorders Reports · 2026-06-30

Jalalian-Javadpour Marzieh, Yekta Batool Ghorbani, Reyhani Niloufar, Hajizamani Shadi, Azizi Ali, Azad Najma Khoshrooz, Mohammadi Hamidreza, Vaseghi Salar

DOI 10.1016/j.jadr.2026.101098

Crossref Published psilocybin OCDSystematic ReviewReview ArticleAnimal Study Systematic Review

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.

Unknown journal · 2026-06-30

Orsini DK, Wong S, Di Luch S, Chan B, Vasudeva S, Lovell GFM, Le GH, Jones BDM, Chisamore N, Mollica A, Johnson DE, Kaczmarek ES, Goel A, Burke MJ, Mansur R, McIntyre RS, Husain MI, Rosenblat JD.

DOI 10.1001/jamapsychiatry.2026.0255 PubMed 41984443

Europe PMC Published psilocybin Clinical TrialRandomized Controlled TrialSystematic ReviewReview Article Randomized Controlled Trial

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.

Palliative medicine · 2026-06-30

Plourde L, Chang SL, Nguyen O, Garel N, Farzin H, Stephan JF, Fallu JS, Dorval M, P3A Research Group

DOI 10.1177/02692163261446141 PubMed 42154482

PubMed Published psilocybin End-of-Life DistressClinical TrialObservational StudySafety Clinical Trial

MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.

Unknown journal · 2026-06-30

Junior WSC, Bezerra KS, Matias EGC, Oliveira JIN, Fulco UL.

DOI 10.1039/d6cp00943c PubMed 42300394

Europe PMC Published psilocybinpsilocin DepressionReceptor PharmacologyDrug Interactions Other

Chemistry/structural biology of psychedelic drugs and their receptor(s).

British journal of pharmacology · 2026-06-30

Gumpper RH, Nichols DE

DOI 10.1111/bph.17361 PubMed 39354889

PubMed Published psilocybin Mechanism of ActionReceptor PharmacologyReview Article Review Article

287 matching results

Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder

This pilot study will evaluate the therapeutic potential of psilocybin in people with Cannabis Use Disorder (CUD). This study will examine the impact of psilocybin treatment on cannabis use and related variables in 12 people with CUD. This is an open-label proof-of-concept trial in which participants will complete a 12-week course of study treatment includin...

ClinicalTrials.gov 2026-03-17 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin Biomarkers Other Cannabis Use DisorderPsilocybin

Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study

Demoralization syndrome is frequently present in palliative care and oncology patients. In particular, up to a third of patients diagnosed with cancer will experience demoralization due to their illness. The relevance of demoralization syndrome in oncology is tied to this syndrome's association with other mental health ailments such as depression, anxiety, s...

ClinicalTrials.gov 2026-03-17 Gustavo Vazquez

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyEnd-of-Life DistressAgingClinical TrialCancer PatientsSafetyAdverse Events Clinical Trial DemoralizationSafety

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to determine the role of psilocybin monitors on the effects of psilocybin therapy in adults with treatment resistant depression....

ClinicalTrials.gov 2026-03-17 Centre for Addiction and Mental Health

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionClinical TrialRandomized Controlled TrialTreatment-Resistant Depression Clinical Trial Treatment-Resistant DepressionPsilocybin

Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease

This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals. This is a pilot study evalu...

ClinicalTrials.gov 2026-03-15 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionReceptor Pharmacology Other Depressive SymptomsDepression

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

The purpose of this study is to determine whether psilocybin, a hallucinogenic drug, is effective in reducing depressive symptoms and amount of drinking in patients with co-occurring Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD). The objectives of this double-blind, placebo-controlled study are to test the hypotheses that a single high (25 m...

ClinicalTrials.gov 2026-03-12 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAddictionHealthcare Workers Clinical Trial Major Depressive DisorderAlcohol Use Disorder

Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health

The purpose of the present study is to evaluate the feasibility, initial signals of efficacy, and potential mechanisms of action of "microdoses" of psilocybin (i.e., low doses of psilocybin that are not believed to produce mystical-type, transcendent, hallucinogenic, or other overtly salient subjective effects that limit functionality) in the treatment of mo...

ClinicalTrials.gov 2026-03-10 University of Alabama at Birmingham

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingMechanism of ActionMicrodosingEmotional ProcessingMystical ExperienceObservational StudyAbuse Liability Clinical Trial DemoralizationPsilocybin

Psilocybin-facilitated Treatment for Chronic Pain

The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life. Investigators will also evaluate potential me...

ClinicalTrials.gov 2026-03-10 University of Alabama at Birmingham

ClinicalTrials.gov CLINICAL TRIAL psilocybin Chronic PainPersonality ChangeEmotional ProcessingMystical ExperienceSafety Clinical Trial FibromyalgiaPrimary

Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study

The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significa...

ClinicalTrials.gov 2026-03-10 Yale University

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyPTSDAddictionOCDReceptor PharmacologyClinical TrialSafetyAdverse Events Clinical Trial TransdiagnosticDepression - Major Depressive Disorder

An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD

This study will examine the safety and preliminary efficacy of psilocybin mushrooms to treat adults with PTSD. Up to 24 participants will take part in this study. Each participant will ingest psilocybin from dried mushrooms in a chocolate formulation.

ClinicalTrials.gov 2026-03-08 Suzanne "Sue" Sisley MD

ClinicalTrials.gov CLINICAL TRIAL psilocybin PTSDPharmacologyClinical TrialSafety Clinical Trial PTSDPsychedelic

The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults

The goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults. Anorexia nervosa is a serious eating disorder that currently has no approved medicine. Psilocybin is a psychedelic substance that may help the brain form new connections, which could make it easier for people ...

ClinicalTrials.gov 2026-03-05 Region Skane

ClinicalTrials.gov CLINICAL TRIAL psilocybin AnxietyEating DisordersNeuroplasticityBrain ImagingMechanism of ActionReceptor PharmacologyDefault Mode NetworkConsciousnessBiomarkersAgingPersonality ChangeEmotional ProcessingMystical ExperienceClinical TrialRandomized Controlled TrialReview ArticleAnimal StudyAdolescentsHealthcare WorkersSafetyAdverse EventsToxicityDrug Interactions Randomized Controlled Trial Anorexia NervosaPsilocybin

Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.

This study will serve as a pilot randomized controlled trial to assess the feasibility of Psilocybin-Assisted Psychotherapy (PAP) in Treating Irritable Bowel Syndrome (IBS). Patients with severe IBS will undergo 3 pre-psychotherapy sessions with two licensed and trained psychedelic therapists, then will be randomized to undergo a guided psychotherapy session...

ClinicalTrials.gov 2026-03-04 NYU Langone Health

ClinicalTrials.gov CLINICAL TRIAL psilocybin Randomized Controlled Trial Randomized Controlled Trial IBS - Irritable Bowel SyndromePsilocybin 25 mg

Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial

The primary aim of this study is to assess the safety and efficacy of psilocybin-assisted therapy in the treatment of post-traumatic stress disorder in United States military Veterans. The objective of this study is to determine the safety and efficacy of psilocybin assisted psychotherapy in the treatment of Veterans with PTSD. This study will recruit 15 Uni...

ClinicalTrials.gov 2026-03-03 Ohio State University

ClinicalTrials.gov CLINICAL TRIAL psilocybin PTSDVeteransSafety Other PTSDStress Disorders

A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.

This study is assessing the efficacy and safety of NPX-5 in psilocybin-assisted psychotherapy for the treatment of adjustment disorder due to cancer diagnosis. Who is it for? This study is for people who are aged between 18 and 80 years old and suffer from anxiety after adjusting to an acutely stressful event of their cancer diagnosis. This is called adjustm...

ClinicalTrials.gov 2026-03-02 Psyence Australia Pty Ltd

ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyClinical TrialSafety Clinical Trial Adjustment DisorderAdjustment Disorder With Anxious Mood

Study of Psilocybin for Anorexia in Young Adults

This is a single site trial of psilocybin therapy for the treatment of refractory Anorexia Nervosa in young adults. The psilocybin therapy will include three preparatory sessions, psilocybin dosing session one (20mg), two integration sessions, psilocybin dosing session two (up to 25mg), and three final integration sessions. Eating disorder symptoms will be m...

ClinicalTrials.gov 2026-03-02 Marissa Raymond-Flesch, MD, MPH

ClinicalTrials.gov CLINICAL TRIAL psilocybin Eating Disorders Other Anorexia NervosaPsilocybin

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

This research study will use computerized tasks, electroencephalography (EEG), and magnetic resonance imaging (MRI) to look at how the drug psilocybin, a naturally occurring compound contained in hundreds of species of psychoactive mushrooms, changes thoughts and brain activity. In this double-blind, placebo-controlled, within-subject, full cross-over study ...

ClinicalTrials.gov 2026-03-01 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin Brain ImagingConsciousnessAgingCreativityHealthy Volunteers Other HealthyPsilocybin

Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment

The goal of this pilot, exploratory, clinical trial is to investigate the effects of psilocybin on synaptic vesicular density (SVD) as measured by the positron emission tomography (PET) radiotracer, 18F-SynVesT-1, in participants with amnestic Mild Cognitive Impairment (aMCI) and healthy participants. The investigators hypothesize that SVD levels in the brai...

ClinicalTrials.gov 2026-02-24 Centre for Addiction and Mental Health

ClinicalTrials.gov CLINICAL TRIAL psilocybin NeuroplasticityBrain ImagingClinical TrialHealthy Volunteers Clinical Trial Amnestic Mild Cognitive ImpairmentPsilocybin

The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.

In this study, participants will received either psilocybin (the active ingredient found in certain mushrooms) or an inactive placebo (a look-alike tablet with no active drug). The psilocybin is supplied by Filament Health (Burnaby, British Columbia). After psilocybin ingestion, the body quickly converts it into psilocin, which is the form that produces the ...

ClinicalTrials.gov 2026-02-24 Gabriella Gobbi

ClinicalTrials.gov CLINICAL TRIAL psilocybinpsilocin Brain ImagingReceptor PharmacologyBiomarkersHealthy Volunteers Other Healthy ParticipantsPlacebo - Control

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with bupr...

ClinicalTrials.gov 2026-02-22 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin AddictionClinical TrialHealthy VolunteersAdverse Events Clinical Trial Opioid Use DisorderPsilocybin

Safety for Home Administration of Microdose Psilocybin Use

The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete qu...

ClinicalTrials.gov 2026-02-22 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin MicrodosingHealthy VolunteersSafety Clinical Trial Psychedelic Experiencespsilocybin trihydrate

Investigation of Psychedelic Effects in Psychoactive Substances

The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will the...

ClinicalTrials.gov 2026-02-22 Johns Hopkins University

ClinicalTrials.gov CLINICAL TRIAL psilocybin Healthy Volunteers Clinical Trial Psychedelic Effects in Healthy VolunteersPlacebo

Email alerts Open a focused sheet to subscribe broadly or narrow notifications by keyword, author, journal, topic, substance, and cited DOI.

Analytics Open a focused analytics workspace for timeline ranges, publication trends, top journals, topics, and authors.

Source	Count	Share	Status
Europe PMC	2,553	64.2%	Active
PubMed	302	7.6%	Active
ClinicalTrials.gov	287	7.2%	Active
OpenAlex	283	7.1%	Active
PsyArXiv	216	5.4%	Active
Crossref	157	4%	Active
bioRxiv	142	3.6%	Active

Psilocybin Research Publication Tracker

Research search

Latest Publications